<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005771</url>
  </required_header>
  <id_info>
    <org_study_id>P-080623-01</org_study_id>
    <nct_id>NCT01005771</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions</brief_title>
  <official_title>GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, parallel-group, dose-finding study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 eligible patients will be included in the double-blind phase (50 in each group,&#xD;
      randomised 1:1:1:1 to GF-001001-00 at a concentration of 0.25%, 1% or 2% or placebo).&#xD;
&#xD;
      Randomised patients will apply the study medication as follows depending on their assigned&#xD;
      treatment group.&#xD;
&#xD;
        -  GF-001001-00 2%, 2 times daily, for 7 days&#xD;
&#xD;
        -  GF-001001-00 1%, 2 times daily, for 7 days&#xD;
&#xD;
        -  GF-001001-00 0.25%, 2 times daily, for 7 days&#xD;
&#xD;
        -  Placebo, 2 times daily, for 7 days&#xD;
&#xD;
      The first application will be done after randomisation at Visit 1 under the guidance of the&#xD;
      investigator. Patients will return for control visits: Visit 2 (Day 5) and Visit 3 (Day 7),&#xD;
      after randomisation. Patients will return for the Final Visit (Visit 4, Day 14 after&#xD;
      initiation of treatment).&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To determine the most effective dose of GF-001001-00 cream for treatment of adult patients&#xD;
      with secondarily infected traumatic lesions.&#xD;
&#xD;
      Primary efficacy endpoint:&#xD;
&#xD;
      Clinical response (success or failure) at the Final Visit (Day 14) in the ITTC population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological cure</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events Clinical laboratory parameters Vital signs</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Secondarily Infected Traumatic Lesions</condition>
  <arm_group>
    <arm_group_label>GF-001001-00 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GF-001001-00 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GF-001001-00 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GF-001001-00</intervention_name>
    <description>GF-001001-00 2%, 1% and 0.25% twice daily for 7 days</description>
    <arm_group_label>GF-001001-00 0.25%</arm_group_label>
    <arm_group_label>GF-001001-00 1%</arm_group_label>
    <arm_group_label>GF-001001-00 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females â‰¥ 18 years of age.&#xD;
&#xD;
          -  Presence of small laceration, sutured wound, abrasion or burn, which has a secondary&#xD;
             bacterial infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatologische Praxis</name>
      <address>
        <city>Mahlow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2009</study_first_posted>
  <last_update_submitted>June 8, 2010</last_update_submitted>
  <last_update_submitted_qc>June 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nuria Albareda</name_title>
    <organization>Ferrer Internacional S.A.</organization>
  </responsible_party>
  <keyword>Secondarily infected traumatic lesions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

